The price of Structure Therapeutics Inc ADR (NASDAQ: GPCR) closed at $34.80 in the last session, down -1.28% from day before closing price of $35.25. In other words, the price has decreased by -$0.45 from its previous closing price. On the day, 561065 shares were traded.
Ratios:
We take a closer look at GPCR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 19.14 and its Current Ratio is at 19.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on October 19, 2023, initiated with a Mkt Outperform rating and assigned the stock a target price of $90.
On July 27, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $58.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GPCR now has a Market Capitalization of 1.62B and an Enterprise Value of 1.16B.
Stock Price History:
Over the past 52 weeks, GPCR has reached a high of $75.02, while it has fallen to a 52-week low of $21.21. The 50-Day Moving Average of the stock is 42.36, while the 200-Day Moving Average is calculated to be 42.93.
Shares Statistics:
According to the various share statistics, GPCR traded on average about 898.07K shares per day over the past 3-months and 911.24k shares per day over the past 10 days. A total of 46.41M shares are outstanding, with a floating share count of 41.16M. Insiders hold about 11.31% of the company’s shares, while institutions hold 81.44% stake in the company. Shares short for GPCR as of Feb 29, 2024 were 3.04M with a Short Ratio of 3.38, compared to 2.33M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.51% and a Short% of Float of 7.74%.
Earnings Estimates
The company has 5 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.22, while EPS last year was -$1.14. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.18 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.83 and -$0.92 for the fiscal current year, implying an average EPS of -$0.87. EPS for the following year is -$0.93, with 6 analysts recommending between -$0.8 and -$1.1.
